Detalles de la búsqueda
1.
Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
J Eur Acad Dermatol Venereol
; 37(11): 2327-2335, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432045
2.
Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
J Eur Acad Dermatol Venereol
; 37(9): 1825-1840, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37147855
3.
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
J Eur Acad Dermatol Venereol
; 37(10): 2016-2027, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37262309
4.
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
Br J Dermatol
; 186(1): 30-39, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33991341
5.
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
J Eur Acad Dermatol Venereol
; 36(2): 228-236, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34628687
6.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
J Eur Acad Dermatol Venereol
; 36(6): 855-865, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35174556
7.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Br J Dermatol
; 184(6): 1047-1058, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880909
8.
Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
J Eur Acad Dermatol Venereol
; 35(8): 1686-1691, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428281
9.
A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
J Eur Acad Dermatol Venereol
; 35(3): 701-711, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32939860
10.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
J Eur Acad Dermatol Venereol
; 35(7): 1562-1568, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711179
11.
[Systemic treatment of moderate/severe hidradenitis suppurativa]. / Systemische Therapie der mittelschweren/schweren Hidradenitis suppurativa.
Hautarzt
; 72(8): 686-691, 2021 Aug.
Artículo
en Alemán
| MEDLINE | ID: mdl-34189590
12.
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment.
Br J Dermatol
; 182(4): 869-879, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31376153
13.
Continued treatment with secukinumab is associated with high retention or regain of response.
Br J Dermatol
; 182(1): 67-75, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30972746
14.
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol
; 183(2): 265-275, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705526
15.
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Br J Dermatol
; 183(2): 231-241, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32316070
16.
Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.
J Eur Acad Dermatol Venereol
; 34(3): 533-541, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31599476
17.
Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.
Br J Dermatol
; 181(6): 1177-1189, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31017657
18.
A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis.
J Eur Acad Dermatol Venereol
; 38(4): e326-e328, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37907283
19.
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
Br J Dermatol
; 177(4): 1014-1023, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28542874
20.
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
Br J Dermatol
; 177(5): 1401-1409, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28636793